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to their visit to General Practitioner. Study population I: Before the implementation 
of guidelines and the educational leaﬂ et. Study population II: After the implementation 
of guidelines and the educational leaﬂ et. Cross-sectional analysis and descriptive 
analyses was performed using the Statistical Package for Social Sciences (SPSS). 
RESULTS: The total number of antibiotic prescriptions for patients suffering from 
U.R.T.I. including sore throat was signiﬁ cantly reduced in the intervention group 
(67% reduction). CONCLUSIONS: A multi-dimensional interventional approach for 
reducing antibiotic prescription in U.A.E. clinics resulted in a signiﬁ cant positive 
outcome. The signiﬁ cant reduction in antibiotic prescriptions indicates the willingness 
of physicians to follow guidelines and the willingness of patients to respond to edu-
cational information.
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OBJECTIVES: To estimate the impact of ocular hypertension (OHT)/primary open-
angle glaucoma (POAG) on health status and quality-of-life. METHODS: Classiﬁ ca-
tion of disease state followed European Glaucoma Society guidelines. Health status 
was based upon the Health Utility Index Mark 3 (HUI3) The National Eye Institute 
25-Item Visual Function Questionnaire (NEI-VFQ-25) was self-administered. Utility 
scores were compared to a normal population matched by age and gender. Differences 
in health impact and quality-of-life between the different disease states were assessed. 
RESULTS: 154 patients were enrolled (27 OHT, 43 early, 35 moderate, 49 advanced 
POAG) from 15 centers in Germany, 137 were diagnosed 35 years ago. Average age 
was 67 ± 11 and 57% were female. 23% of patients had cardiovascular co-morbidity, 
45% history of cataract, 45% hypertension, 18% diabetes, and 10% hypotension. 
Differences in baseline characteristics were seen for age (60, 63, 69, 72 years), history 
of cataract (24%, 25%, 54%, 62%), employment status (43%, 24%), and hypoten-
sion (14%, 0%, 14%, 15%). The HUI3 score for OHT, early, moderate and advanced 
POAG was 0.87 ± 0.09, 0.85 ± 0.15, 0.75 ± 0.23 and 0.58 ± 0.32, respectively. There 
was no difference in the health utility score for patients with OHT, early POAG and 
the normal population. Patients with moderate and advanced POAG were lower by 
0.06 ± 0.24 and 0.19 ± 0.28, signiﬁ cantly different from OHT and early POAG (P < 
0.01). The NEI-VFQ-25 for OHT and early POAG gave ocular symptoms and mental 
health the lowest scores. For moderate POAG the lowest scores were for driving, 
ocular symptoms, mental health, role limitation and peripheral vision. For advanced 
POAG, all domains, except color vision, were affected. CONCLUSIONS: Disease 
progression in glaucoma affects not only vision, but also quality-of-life. Whereas OHT 
and early POAG have little effect on quality-of-life, moderate and advanced POAG 
do. These ﬁ ndings can improve doctor-patient relationships, addressing quality-of-life 
issues for different glaucoma disease states.
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OBJECTIVES: The aim of the current study was to develop an algorithm to map the 
symptom domain of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire 
to a preference based utility index. METHODS: Data from an IDEEL psychometric 
validation study including 210 participants (130 dry eye patients, 32 Sjogren’s patients 
and 48 controls) were used to estimate the algorithm. Participants completed the 
IDEEL, EQ-5D and SF-36 at 2 time points; the ﬁ rst time point was used to estimate 
the algorithm and the second to validate the algorithm. The mapping work was 
preceded by determining bivariate correlations between the IDEEL items and each 
utility index (EQ-5D and SF-6D), and then examining the sensitivity of each index to 
variability in dry eye severity. Initial items were selected based on levels of missing 
data, ﬂ oor and ceiling effects and correlations with the utility index. Items were then 
included in an OLS regression model with age and gender interaction terms. Following 
the item analysis the same procedures were applied to a domain level analysis. 
RESULTS: Based on the criteria outlined above, the SF-6D was selected as the utility 
index for the mapping algorithm. The ﬁ nal OLS regression model contained 2 IDEEL 
symptoms items and age, and explained 28% of the variance in SF-6D utility values; 
root mean squared error (RMSE) = 0.105. As the SF-6D data included few bounded 
or censored estimates Tobit and CLAD models were not estimated. The validation 
data set demonstrated a signiﬁ cant correlation between the predicted and observed 
SF-6D utility values (r = 0.53, p < 0.001). CONCLUSIONS: This algorithm forms a 
good basis to estimate utility values from the IDEEL for inclusion in cost-effectiveness 
analysis.
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OBJECTIVES: To identify and review published utility estimates in atopic dermatitis 
(AD), and to catalogue the methods of utility assessment, patient populations studied, 
and economic evaluations incorporating the utility estimates. METHODS: A system-
atic search and review of the published literature, including health technology assess-
ments, in AD was performed. Utility search terms were those recommended by NICE 
in the UK Publications were limited to English language only, from 1999 through 
2010. RESULTS: Fourteen studies presenting 15 different sets of utility data in AD 
(one study used two separate methods to generate estimates) were identiﬁ ed. These 
14 studies are summarized in 11 separate publications (one health technology assess-
ment describes three otherwise unpublished utility studies). All studies but one present 
utility estimates (vs changes in utility). Two studies present a single utility estimate 
for AD. One study presents utility estimates for controlled vs. uncontrolled AD. All 
other studies present utility estimates by AD severity (e.g., clear, mild, moderate, 
severe), although only two studies link AD severity directly to IGA scores. Two studies 
present utility estimates for children. AD utilities have been collected or applied in 
economic evaluations in Canada, Germany, Sweden, the UK, and the US. Utilities in 
AD have been collected directly using SG, TTO, VAS (with the VAS results being 
converted into utilities for use in economic evaluations using an algorithm that reﬂ ects 
attitudes towards risk), and using the EQ5D. Three studies have generated utility 
estimates based on applying two separate published algorithms to SF-12 or SF6D data. 
Five sets of utility data have been used in economic evaluations. CONCLUSIONS: 
There are several published studies presenting utility estimates in AD; however, they 
vary greatly in terms of methods employed. Economic evaluations in AD, the results 
of which are sensitive to uncertainty in utility inputs, have relied on various 
estimates.
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OBJECTIVES: The assessment of quality of life (QoL) in dermatology is becoming 
increasingly popular as demonstrated by the creation and development of numerous 
questionnaires for the principal diseases of the skin. Paradoxically, although cosmetic 
dermatology is rapidly developing, there is no questionnaire to assess the impact of 
these products on the QoL of the women that use them. There was therefore a need 
for the creation of the Cosmeti QoL. METHODS: The questionnaire was developed 
using rigorous methodology in accordance with international standards in terms of 
quality of life. a literary review and face-to-face interviews were conducted to identify 
the concepts that preoccupied women over 25 years of age. Twenty-two items were 
identiﬁ ed after the ﬁ rst transcription; this was reduced to 12 items after an initial 
analysis making it easier to use. a representative population of 1002 French women 
aged 25 years and over, was put together by the CSA Santé institute using the quota 
method. They were given the Cosmeti QoL; the lower the score the better the Qol. 
RESULTS: The questionnaire is easy to use, good comprehension of the questions was 
observed. The Cosmeti QoL score is correlated to age. An improved QoL is seen in 
women who frequently use a moisturizing cream (13.7 vs. 14.23, P < 0.001). Sensitive 
skin resulted in poorer QoL (14.77 vs. 13.34 P < 0.001), the frequency of episodes 
of sunburn during childhood also reduced the QoL (14.96 vs. 13.86 P < 0.001). In 
the population over 65 years of age, the QoL was superior in women who claimed to 
use cosmetic, anti-wrinkle, or moisturizing products on a regular basis. CONCLU-
SIONS: The Cosmeti QoL scale, which is essentially based on the women’s point of 
view, is a valid, pertinent, and well accepted tool enabling the assessment of quality 
of life perceived through the skin.
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OBJECTIVES: No consensus on deﬁ nition of plaque psoriasis severity currently exists. 
Although standard measures of psoriasis severity are commonly used in clinical prac-
tice, they are not consistent and rarely based on patient assessment. The objective was 
to develop an instrument assessing patient and physician perceptions of psoriasis 
severity and treatment effect. METHODS: Semi-directive exploratory interviews were 
conducted with 20 patients with mild to severe plaque psoriasis, and with 20 derma-
tologists. Interviews’ transcripts were analyzed to extract and organise into models 
the criteria used by patients and physicians to evaluate psoriasis severity and treatment 
beneﬁ t. Items were generated using patient words for each concept considered relevant 
by both patients and dermatologists. The instrument was developed in parallel for 
patients and for physicians, tested for relevance and comprehension on 5 patients and 
5 physicians, and revised accordingly. The new version was tested on 5 new patients 
and 5 new physicians and revised to create a pilot version. a dermatologist advisory 
board was involved at each step of the instrument development. RESULTS: The test 
instrument consisted in 31 items including area involvement, lesion location, signs and 
symptoms (frequency, duration of lesions, joint involvement), treatment history, 
quality of life impact, rapidity and duration of treatment beneﬁ t, and patient satisfac-
tion. The instrument was globally well-accepted by patients and physicians; few 
modiﬁ cations were made. a 32-item pilot version resulted from the comprehension 
